12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cytokinetics, Astellas deal

Astellas and Cytokinetics partnered to develop and commercialize skeletal muscle activators to treat diseases and conditions with muscle weakness in a deal worth up to $490 million. The partners will jointly work to identify and optimize fast skeletal troponin activators and other skeletal muscle activators with...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >